Results 161 to 170 of about 4,153 (212)
Efficacy and safety of finerenone combined with sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease: protocol for a systematic review and meta-analysis. [PDF]
BMJ OpenWang X, Yu Y, Xiang Y, Liu X, Yu R.
europepmc +1 more source
Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis. [PDF]
Cardiovasc Diabetol Endocrinol RepShokravi A, Seth J, Lu N, Mancini GBJ.
europepmc +1 more source
Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction. [PDF]
Int J Heart FailValente V, Beer BN, Savarese G.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Vnitřní lékařství, 2023
In developed countries, diabetes mellitus (DM) is one of the main causes of end stage renal disease (ESRD). In addition, the development of chronic kidney disease (CKD) further increases the already significantly increased cardiovascular (CV) risk in patients with diabetes.
Jan, Vachek, Vladimír, Tesař
openaire +3 more sources
In developed countries, diabetes mellitus (DM) is one of the main causes of end stage renal disease (ESRD). In addition, the development of chronic kidney disease (CKD) further increases the already significantly increased cardiovascular (CV) risk in patients with diabetes.
Jan, Vachek, Vladimír, Tesař
openaire +3 more sources
Drugs, 2021
Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare Pharmaceuticals for the treatment of diabetic kidney disease (DKD) and heart failure (HF), including chronic HF (CHF).
openaire +2 more sources
Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare Pharmaceuticals for the treatment of diabetic kidney disease (DKD) and heart failure (HF), including chronic HF (CHF).
openaire +2 more sources
Dialyse aktuell, 2021
Die diabetische Nephropathie, eine Manifestation der diabetischen Mikroangiopathie, ist weiterhin die häufigste Ursache der terminalen dialysepflichtigen Niereninsuffizienz in den Industrienationen. Dies zeigen u. a. aktuelle Daten des Registers der „European Renal Association – European Dialysis and Transplant Association“ (ERA-EDTA) 1.
openaire +1 more source
Die diabetische Nephropathie, eine Manifestation der diabetischen Mikroangiopathie, ist weiterhin die häufigste Ursache der terminalen dialysepflichtigen Niereninsuffizienz in den Industrienationen. Dies zeigen u. a. aktuelle Daten des Registers der „European Renal Association – European Dialysis and Transplant Association“ (ERA-EDTA) 1.
openaire +1 more source
pharma-kritik, 2022
Als erster nicht-steroidaler Mineralokortikoid-Rezeptorantagonist (MRA) beeinflusst Finerenon (Kerendia®) die Nierenfunktion bei Personen mit einem Typ-2-Diabetes und Niereninsuffizienz vorteilhaft. Weitere Untersuchungen müssen zeigen, ob mit der neuen Substanz mehr als z.B. mit Eplerenon (Inspra® u.a.) erreicht wird.
openaire +1 more source
Als erster nicht-steroidaler Mineralokortikoid-Rezeptorantagonist (MRA) beeinflusst Finerenon (Kerendia®) die Nierenfunktion bei Personen mit einem Typ-2-Diabetes und Niereninsuffizienz vorteilhaft. Weitere Untersuchungen müssen zeigen, ob mit der neuen Substanz mehr als z.B. mit Eplerenon (Inspra® u.a.) erreicht wird.
openaire +1 more source
Canadian Journal of Health Technologies, 2023
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
Cardiovascular Events with Finerenone in CKD and Diabetes
New England Journal of Medicine, 2022Alberto, Ortiz +2 more
exaly +6 more sources
New Drugs Update: Finerenone, Difelikefalin, and Avacopan
The Senior Care Pharmacist, 2022Three drugs are discussed in this article: finerenone, difelikefalin, and avacopan. Finerenone (Kerendia™) is FDA-indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease (ESKD), cardiovascular (CV) death, non-fatal myocardial infarction (MI), and hospitalization for heart failure (HF) in ...
openaire +2 more sources